Weight loss drugmaker Novo Nordisk (NVO) on Friday announced that its CEO, Lars Fruergaard Jørgensen, will resign from his leadership role as the company searches for his successor. NVO said the ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press conference in Copenhagen: "You ain't seen nothing yet." ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...

COPENHAGEN/LONDON (Reuters) -Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press conference in Copenhagen: "You ain't seen nothing ...

Novo Nordisk's Former Chief Makes Comeback to Steer Choice of New CEO By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Years before Novo Nordisk's obesity drug Wegovy became ...

Novo Nordisk (NVO) isn’t just changing CEOs — it’s pulling a seasoned heavyweight back into the ring to help decide who comes next. Former chief Lars Rebien Sørensen, who led the pharma ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

With the withdrawal of the U.S., the WHO has lost its top donor. Helping compensate for the shortfall are the Novo Nordisk Foundation and China.

Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...